Status:
UNKNOWN
The Assessment of Progression of Paroxysmal AF After CABG
Lead Sponsor:
Meshalkin Research Institute of Pathology of Circulation
Conditions:
Paroxysmal Atrial Fibrillation, Coronary Artery Disease
Eligibility:
All Genders
18-80 years
Phase:
PHASE3
Brief Summary
The aim of this study is a comparative evaluation of progression of paroxysmal atrial fibrillation in patients with coronary artery disease after isolated CABG and CABG combined with pulmonary vein is...
Detailed Description
This is a single blinded prospective randomized study involving 72 patients with paroxysmal AF and coronary artery disease. 72 patients are required to have a 80% chance of detecting, as significant a...
Eligibility Criteria
Inclusion
- American College of Cardiology (ACC)/ American Heart Association (AHA) -Indications for CABG
- At least 2 ECG-verified (12-channel ECG, Holter telemetry) symptomatic paroxysmal atrial fibrillation episodes within last 12 months
- The patient's consent to participate in the study
Exclusion
- Intolerance of antiarrhythmic drugs
- Heart valve disease requiring invasive treatment
- Left atria more than 6.5 cm
- Prior cardiac surgery
- Active pacemaker treatment
- Active anti-arrhythmic treatment (AAD) class I and III
- Contraindication to oral anticoagulant/heparin treatment
- Ejection fraction less than 30 % (EF \< 30 %) assessed by transthoracic echocardiography
Key Trial Info
Start Date :
January 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2017
Estimated Enrollment :
72 Patients enrolled
Trial Details
Trial ID
NCT02246803
Start Date
January 1 2014
End Date
December 1 2017
Last Update
September 23 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Meshalkin State Research Institute of Circulation Pathology
Novosibirsk, Russia, 630055